8-K
false 0001661998 0001661998 2020-06-10 2020-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2020

 

HOMOLOGY MEDICINES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

 

001-38433

 

47-3468154

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

One Patriots Park
Bedford, MA

 

01730

(Address of principal executive offices)

 

(Zip Code)

(781) 301-7277

(Registrant’s telephone number, include area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock,

$0.0001 par value per share

 

FIXX

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 10, 2020, Homology Medicines, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 43,247,091 shares of common stock were present online or represented by proxy at the meeting, representing approximately 95.7% percent of the Company’s outstanding common stock as of the April 17, 2020 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020.

Item 1 — Election of three Class II Directors to serve until the 2023 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

NOMINEE

 

Votes FOR

 

Votes WITHHELD

 

Broker Non-Votes

Steven Gillis, Ph.D.

 

36,671,773

 

2,011,744

 

4,563,574

Richard J. Gregory, Ph.D.

 

37,237,578

 

1,445,939

 

4,563,574

Kush M. Parmar, M.D, Ph.D.

 

36,912,102

 

1,771,415

 

4,563,574

Item 2 — Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020.

Votes FOR

 

Votes AGAINST

 

Votes ABSTAINED

 

Broker Non-Votes

43,166,375

 

49,235

 

31,481

 

0

Based on the foregoing votes, Steven Gillis, Ph.D., Richard J. Gregory, Ph.D. and Kush M. Parmar, M.D, Ph.D. were elected as Class II Directors and Item 2 was approved.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HOMOLOGY MEDICINES, INC.

 

                 

Date: June 11, 2020

 

 

By:

 

/s/ W. Bradford Smith

 

 

 

 

W. Bradford Smith

 

 

 

 

Chief Financial Officer and Treasurer